Oncopeptides (OND) Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
OND Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.14 |
| 52 Week High | SEK 0.56 |
| 52 Week Low | SEK 0.11 |
| Beta | -1.31 |
| 1 Month Change | 4.51% |
| 3 Month Change | -13.61% |
| 1 Year Change | -68.13% |
| 3 Year Change | -80.54% |
| 5 Year Change | -96.72% |
| Change since IPO | -96.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| OND | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -15.2% | -0.8% | -1.8% |
| 1Y | -68.1% | -4.9% | 4.2% |
Return vs Industry: OND underperformed the German Biotechs industry which returned -4.9% over the past year.
Return vs Market: OND underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| OND volatility | |
|---|---|
| OND Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: OND's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OND's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 69 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.
Oncopeptides AB (publ) Fundamentals Summary
| OND fundamental statistics | |
|---|---|
| Market cap | €57.61m |
| Earnings (TTM) | -€18.92m |
| Revenue (TTM) | €8.46m |
Is OND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OND income statement (TTM) | |
|---|---|
| Revenue | SEK 95.15m |
| Cost of Revenue | SEK 3.43m |
| Gross Profit | SEK 91.73m |
| Other Expenses | SEK 304.69m |
| Earnings | -SEK 212.96m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 96.40% |
| Net Profit Margin | -223.81% |
| Debt/Equity Ratio | 542.3% |
How did OND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 02:39 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |